Compare NWBI & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWBI | TNDM |
|---|---|---|
| Founded | 1896 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2013 |
| Metric | NWBI | TNDM |
|---|---|---|
| Price | $11.99 | $22.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $14.00 | ★ $24.00 |
| AVG Volume (30 Days) | 853.5K | ★ 1.5M |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | ★ 13.78 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | $564,562,000.00 | ★ $1,007,001,000.00 |
| Revenue This Year | $7.91 | $8.59 |
| Revenue Next Year | $9.01 | $10.19 |
| P/E Ratio | $14.01 | ★ N/A |
| Revenue Growth | 15.71 | ★ 17.87 |
| 52 Week Low | $10.75 | $9.98 |
| 52 Week High | $13.62 | $38.28 |
| Indicator | NWBI | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 59.16 |
| Support Level | $12.64 | $21.97 |
| Resistance Level | $12.90 | $22.68 |
| Average True Range (ATR) | 0.18 | 0.96 |
| MACD | -0.08 | -0.16 |
| Stochastic Oscillator | 3.76 | 44.36 |
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.